Durvalumab cost-effectiveness in limited-stage small cell lung cancer failed to meet US value thresholds despite longer ...
Lowered costs and incremental effectiveness could improve when using biomarker-guided selection for treatment of patients with metastatic colorectal cancer using first-line nivolumab. Choosing the ...
Home-based self-sampling for squamous cell carcinoma of the anus could be a cost-effective way to increase screening among ...
Sotorasib is more cost-effective in treating patients with KRAS G12C non–small cell lung cancer (NSCLC) compared with adagrasib in second- and subsequent-line treatment, accordi ...
The anti-cancer drug durvalumab used in immunotherapy delivers a 66-month survival breakthrough for lung cancer patients, ...
Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal ...
Usual care provided 9.59 QALYs at a lifetime cost of $222,300, diet and exercise yielded 9.75 QALYs for $226,300, and semaglutide offered 10.48 QALYs at $273,500, with tirzepatide providing 10.68 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback